Cargando…
Ceftolozane-Tazobactam Resistance in Multidrug-Resistant Pseudomonas aeruginosa Isolates Not Associated with AmpC Activity
BACKGROUND: Ceftolozane-tazobactam (CT) is a newly approved cephalosporin/β-lactamase inhibitor combination with excellent in vitro activity against multidrug-resistant (MDR) P. aeruginosa. Unfortunately, CT-resistance (CT-R) has already been reported. In this work, we evaluate mutational pathways a...
Autores principales: | Tran, Truc T, Diaz, Lorena, Abodakpi, Henrietta, Ardila, Javier, Cadena, Elsa De La, Rios, Rafael, Miller, William, Rivas, Lina, Dinh, An, Porras, Paola, Panesso, Diana, Tam, Vincent, Munita, Jose M, Arias, Cesar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631879/ http://dx.doi.org/10.1093/ofid/ofx163.175 |
Ejemplares similares
-
In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways
por: Skoglund, Erik, et al.
Publicado: (2018) -
Corrigendum to “In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways”
por: Skoglund, Erik, et al.
Publicado: (2019) -
Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling
por: Deroche, Luc, et al.
Publicado: (2023) -
1608. Efficacy of Ceftolozane/Tazobactam for Multidrug-Resistant Gram-Negative Infections in Multiple Urban Hospitals
por: Cabrera, Nicolo, et al.
Publicado: (2020) -
1592. In Vitro Activity of Ceftolozane/Tazobactam (C/T) Against Enterobacteriaceae and Pseudomonas aeruginosa Circulating in Chile
por: Rivas, Lina M, et al.
Publicado: (2019)